BUZZ-Tekmira Pharmaceuticals: Acquisition to boost Hep B drugs portfolio
** Canadian biopharmaceutical company's U.S.-listed shares up 43 pct at $22.40 premarket
** Tekmira to buy OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods
** Implied market value of the merged company is about $750 mln, OnCore shareholders will hold 50 pct of Tekmira
** Tekmira to continue with its oncology and anti-viral programs, including Ebola
** On Sept. 22, the FDA authorized emergency use of Tekmira's Ebola treatment, but its shares have fallen 33 pct since then through Friday's close
© Thomson Reuters 2017 All rights reserved.